# Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere

> **Open Intelligence Dossier** · First detected: 2026-10-05 20:40 UTC · Category: Business

## Executive Summary
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.

## Intelligence Brief
Recent coverage details new phase 2 clinical trial results released by Genmab concerning its antibody-drug conjugate, known as Rinatabart Sesutecan or Rina-S. According to reporting from Business Wire and Fierce Biotech, the RAINFOL-01 trial evaluated Rina-S in patients diagnosed with platinum-resistant ovarian cancer. Endpoints News and The Pharma Letter note that the data demonstrate durable and clinically meaningful responses, with TradingView reporting an overall response rate of forty-five point nine percent. European Biotechnology Magazine highlights that these findings strengthen the case for Genmab&amp;#039;s prior financial investment, specifically pointing to an eighteen-hundred-million-dollar bet on ProfoundBio. The emerging conversation in the trades also draws direct comparisons between Genmab&amp;#039;s product and existing therapies in the same space.


Fierce Biotech&amp;#039;s coverage brings attention to claims suggesting the antibody-drug conjugate is clearly superior to AbbVie&amp;#039;s Elahere. Additional reporting from Endpoints News links the Genmab data release with unrelated regulatory updates, such as label expansions for Eli Lilly&amp;#039;s Jaypirca. Outlets like TradingView have categorized these announcements within weekly market recaps, which also touch upon unrelated corporate developments such as Darwin Global&amp;#039;s voting control metrics. Context provided across the reporting sources emphasizes the high stakes within the oncology therapeutics market, particularly regarding treatments for platinum-resistant ovarian cancer. Coverage does not yet specify the full timeline for subsequent regulatory submissions or upcoming late-stage trial milestones, leaving open questions about how quickly Genmab plans to advance the drug toward commercialization or pivotal review stages.


Observers tracking the sector are looking toward upcoming medical congress presentations and corporate updates from Genmab for further details on the Rina-S program. Business Wire and other specialized outlets indicate that future disclosures will likely provide deeper dives into safety profiles, progression-free survival data, and comparative analyses with competing therapies like Elahere. Coverage does not yet specify whether regulatory authorities have granted any expedited review statuses or when the formal trial completion date will be officially reached.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| European Biotechnology Magazine | Genmab’s Phase 2 data strengthens case for $1.8B ProfoundBio bet | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxNeF9BeVlEUXBKV0ZrekdhY2l0Tzctc3pIcWF2c0lGdEh3NHI0VlJhV0xKRms5b1VJN1RkMzd0TWREQWVoSzFXbkJqZ2lMb1otZTJBZnNzMmJtWTVHVHBJX2d5V0llZW9OclBjTGZzbDdlTU94RXFVU2dBVjhBbU5oWEhpQzl1bWVUalRya3Eza1ROOUFTTUxpQUFFamozRkhpS1J1QzdhaGFJbFhJTVhj?oc=5) |
| Endpoints News | Genmab details ovarian cancer data; Lilly’s Jaypirca gets a label expansion | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxOQTZZMzlkb1dNZmRlSC1zWU9UVzZJNVozMHYwOFRVSGl3RF9PcU03dDd6bE92VmVYY3B2Wk9UV1dwYklFQm1qSkVIMzNmTFRsT3poN1B3UlJRUUljRHIzc0dRR3RsY2N0MENZd3JVTzlQZm8xTUxlUnNBdllZT081YzMtczZodjhFakhuNVFuaFFwcG85Y0lXMkh3Z3psQQ?oc=5) |
| TradingView | Weekly Recap: Rina‑S 45.9% ORR and Darwin Global 5.11% voting control | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxPYnNKTTFqOXRER29yMHZCZjNnZE01Njh4dkMzYnIzaVB5T3NQVE5lUHFyZ084VXNEeXF1U01MSkY0MTM1NXNpTmsxSV9sTkZyWkU2QUQ3dU1fN2RlN202ajJEdmt3Y1p1dWlXLWxVR0ZNbnpjSXVmdXhFV3UycDZvSnBUbTRodmVCTGhmMnNwUS1pWl9SSEl0NEZJZHBpRXR5QmM2NXRLaEc1SjNiTnJGWng0TTFmZC1VbklfbWYwbXV0VUxQVVo4?oc=5) |
| The Pharma Letter | Genmab’s Rina-S shows durable responses in ovarian cancer | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxOQlpLUTJTYWhxQmM5ZXVHTkp2WDhvVlRZTkhPazh6T2J2U2V5MEdGRHZpNEtkMWhQQXQyS3dWbjZ4YWxNRl9LSnc2ZmEwbFJ0TFNXTXRNV1Z1NTdLTU1wbUliSVF6OC1hU2ltVERkTnNabTMtcnNrZENlUk1hMTJ3LUp2RWxZSGN2ZE1BNWc2aW5KdjdHTkduSExvQVcyenBwcWdZ?oc=5) |
| Business Wire | Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer | [Source Link](https://news.google.com/rss/articles/CBMi1wJBVV95cUxOb0RfRzlGOUdMSGY2S1pkXzlXS3ZJRm1fWlJrWDhIUnA4WjQ5Y3VLbm80eEhiRmo4QzZJaW81V3NJWE9nbGZiYm5yUGZUUkdNQ3VQZ3ZFMHU0ZGZKdndlb3g3VThqSHBVb3h0Y2I1MnFMX00yRzhiSW1NZUJHdHVLQUczM21NZlJ2clVVLWxpLW1zUWV1eC03QWRKV2xhMWVZNHlfeTJ3cm9iSmV0MkRJeDduZjMtUG1DYVZ3SFBsUWV5MmZCYlRvRkFGbGcxRWl2VHZjVWxVZGYzck1xY3VDdVJHNGgyTmxyVXlELVNJUFRnd0FzUFc5M2YwMS1Cdlc0S3FNczMwSV9IX3F0RkpCQ0RFTTVoQXZGV19XOUxsNGpsMGdjOThTYi1IcHdZWng3THhhOHQtU3dWNDI5Zl9sSGN2UTFzZWxLUURFZS1PaG5KRy1SbHJ) |
| Fierce Biotech | Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxNaVVhNWU5c3BuNjJkdnpGMGEtcUV1ZjNFcG92ZnZCM2R6SE42VDJPSUhpcTVLZmY1UHdBWjBsWktlVUc0ZnZOQzYwNDEzbEFvanZNVFE3SVdFSjZJMVh5SGxiaHViQTYzLWxUWEdiWVJOT2h4eGhnek1fZ1RrV1o2ZXlBdVJ2YzhFejlEaDJhWFVCdml1M2czN1hIYjlzUQ?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-05/genmab-s-latest-phase-2-data-spur-claim-adc-is-clearly-superior-to-abbvie-s*
